Is It Feasible?
But, simply because PSMA-PET/CT does a better job at detection and diagnosing metastases than current conventional methods, that doesn’t mean all patient-care environments can necessarily implement it. Cost will likely play a large role in whether patients will have wide-spread access to the scans.
“Costs associated with PSMA-PET/CT vary in different regions of the world, but this approach may offer savings over conventional imaging techniques,” said co-author Roslyn Francis with the University of Western Australia. “A full health-economic analysis will help to determine the cost effectiveness of introducing PSMA-PET/CT, both from a patient and a healthcare perspective.”
Completing an economic analysis will be critical, Caroline Moore, professor of urology at the University College London, wrote in accompanying editorial.
“Introduction of novel imaging into routine practice requires careful assessment of the potential burden to both individuals and to society, taking into account change in treatment which can result,” Moore wrote. “The proPSMA authors have planned an economic analysis of the potential effect of replacing conventional staging with PSMA-PET, which will be crucial in assessing the feasibility of widespread use of PSMA-PET/CT in men being considered for radical treatment for high-risk prostate cancer.”